CD133+ liver cancer stem cells from methionine adenosyl transferase 1A–deficient mice demonstrate resistance to transforming growth factor (TGF)-β–induced apoptosis #
Open Access
- 27 March 2009
- journal article
- research article
- Published by Wolters Kluwer Health in Hepatology
- Vol. 49 (4) , 1277-1286
- https://doi.org/10.1002/hep.22743
Abstract
Methionine adenosyltransferase (MAT) is an essential enzyme required for S-adenosylmethionine biosynthesis. Hepatic MAT activity falls during chronic liver injury, and mice lacking Mat1a develop spontaneous hepatocellular carcinoma by 18 months. We have previously demonstrated that CD133+CD45− oval cells isolated from 16-month-old Mat1a −/− mice represent a liver cancer stem cell population. The transforming growth factor β (TGF-β) pathway constitutes a central signaling network in proliferation, apoptosis, and tumorigenesis. In this study, we tested the response of tumorigenic liver stem cells to TGF-β. CD133+CD45− oval cells were isolated from premalignant 16-month-old Mat1a −/− mice by flow cytometry and expanded as five clone lines derived from a single cell. All clone lines demonstrated expression of both hepatocyte and cholangiocyte markers and maintained a small population (0.5% to 2%) of CD133+ cells in vitro, and three of five clone lines produced tumors. Although TGF-β1 inhibited cell growth equally in CD133− and CD133+ cells from each clone line, the CD133+ population demonstrated significant resistance to TGF-β–induced apoptosis compared with CD133− cells. Furthermore, CD133+ cells demonstrated a substantial increase in mitogen-activated protein kinase (MAPK) pathway activation, as demonstrated by phosphorylated extracellular signal-regulated kinase levels before and after TGF-β stimulation. MAPK inhibition using mitogen-activated protein kinase kinase 1 (MEK1) inhibitor PD98059 led to a significant increase in TGF-β–induced apoptosis in CD133+ cells. Conversely, a constitutively active form of MEK1 blocked the apoptotic effects of TGF-β in CD133− cells. Conclusion: CD133+ liver cancer stem cells exhibit relative resistance to TGF-β–induced apoptosis. One mechanism of resistance to TGF-β–induced apoptosis in CD133+ cancer stem cells is an activated mitogen-activated protein kinase/extracellular signal-regulated kinase pathway. (Hepatology 2009.)Keywords
This publication has 40 references indexed in Scilit:
- Expansion of liver cancer stem cells during aging in methionine adenosyltransferase 1A–deficient mice†Hepatology, 2007
- CD133+ HCC cancer stem cells confer chemoresistance by preferential expression of the Akt/PKB survival pathwayOncogene, 2007
- A CD133-Expressing Murine Liver Oval Cell Population with Bilineage PotentialThe International Journal of Cell Cloning, 2007
- Disruption of transforming growth factor-β signaling through β-spectrin ELF leads to hepatocellular cancer through cyclin D1 activationOncogene, 2007
- Identification and Characterization of Tumorigenic Liver Cancer Stem/Progenitor CellsGastroenterology, 2007
- Establishment of Clonal Colony-Forming Assay for Propagation of Pancreatic Cancer Cells With Stem Cell PropertiesPancreas, 2007
- Role of S‐adenosyl‐L‐methionine in liver health and injury†Hepatology, 2007
- Identification of Putative Stem Cell Markers, CD133 and CXCR4, in hTERT–Immortalized Primary Nonmalignant and Malignant Tumor-Derived Human Prostate Epithelial Cell Lines and in Prostate Cancer SpecimensCancer Research, 2007
- Transforming growth factor-beta differentially regulates oval cell and hepatocyte proliferationHepatology, 2007
- Side population purified from hepatocellular carcinoma cells harbors cancer stem cell–like propertiesHepatology, 2006